← Leaderboards
Emily Y Chew
National Eye Institute
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at National Eye Institute
Same institution · by research overlap
Others in their field
Top investigators on “Participant”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Jeffrey P Krischer · University Of South Florida$407,724,307
- Lawrence Corey · Fred Hutchinson Cancer Center$333,313,234
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Gary D Acton · University Of California-Davis$320,373,312
- Albert Lazzarini · California Institute Of Technology$300,431,866
Research focus
ParticipantDiabetic RetinopathyFundusBlindnessDesignFollow-UpEnrollmentProtocols DocumentationAge Related Macular DegenerationSecondary OutcomePrimary OutcomeVisual AcuityRetinaPersonsClinical TrialsMeasurementFundus PhotographyAffectOphthalmic Examination And EvaluationMaculaHuman SubjectPublishingVisionElderly
Grant awards (135)
AMD Ryan Initiative Study (ARIS)$39,601
ZIA · FY2025 · EY · contact PI
A Phase I/II Trial for Intravitreous Treatment of Severe Ocular von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab (16-EI-0159)$36,001
ZIA · FY2025 · EY · contact PI
Phase 2 Clinical Trial of Ciliary Neurotrophic Factor (CNTF) for Macular Telangiectasia Type 2 (MacTel) (14-EI-0078, 17-EI-0136)$36,001
ZIA · FY2025 · EY · contact PI
A Phase I/IIa Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis$36,001
ZIA · FY2025 · EY · contact PI
Age-Related Eye Disease Follow-up Study (AREDS) Follow-up Study$36,001
ZIA · FY2025 · EY · contact PI
ACCORD (Action to Control Cardiovascular Risk in Diabetes)$36,001
ZIA · FY2025 · EY · contact PI
A Phase 3 Multicenter, Randomized, Sham-Controlled Study to Determine the Safety and Efficacy of Renexus in Macular Telangiectasia Type 2$18,000
ZIA · FY2025 · EY · contact PI
AMD Ryan Initiative Study (ARIS)$44,748
ZIA · FY2024 · EY · contact PI
A Phase I/IIa Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis$40,680
ZIA · FY2024 · EY · contact PI
Age-Related Eye Disease Follow-up Study (AREDS) Follow-up Study$40,680
ZIA · FY2024 · EY · contact PI
ACCORD (Action to Control Cardiovascular Risk in Diabetes)$40,680
ZIA · FY2024 · EY · contact PI
A Phase I/II Trial for Intravitreous Treatment of Severe Ocular von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab (16-EI-0159)$40,680
ZIA · FY2024 · EY · contact PI
Phase 2 Clinical Trial of Ciliary Neurotrophic Factor (CNTF) for Macular Telangiectasia Type 2 (MacTel) (14-EI-0078, 17-EI-0136)$40,680
ZIA · FY2024 · EY · contact PI
A Phase 3 Multicenter, Randomized, Sham-Controlled Study to Determine the Safety and Efficacy of Renexus in Macular Telangiectasia Type 2$20,340
ZIA · FY2024 · EY · contact PI
AMD Ryan Initiative Study (ARIS)$42,341
ZIA · FY2023 · EY · contact PI
A Phase I/IIa Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis$38,492
ZIA · FY2023 · EY · contact PI
A Phase I/II Trial for Intravitreous Treatment of Severe Ocular von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab (16-EI-0159)$38,492
ZIA · FY2023 · EY · contact PI
Age-Related Eye Disease Follow-up Study (AREDS) Follow-up Study$38,492
ZIA · FY2023 · EY · contact PI
Phase 2 Clinical Trial of Ciliary Neurotrophic Factor (CNTF) for Macular Telangiectasia Type 2 (MacTel) (14-EI-0078, 17-EI-0136)$38,492
ZIA · FY2023 · EY · contact PI
ACCORD (Action to Control Cardiovascular Risk in Diabetes)$38,492
ZIA · FY2023 · EY · contact PI
A Phase 3 Multicenter, Randomized, Sham-Controlled Study to Determine the Safety and Efficacy of Renexus in Macular Telangiectasia Type 2$19,246
ZIA · FY2023 · EY · contact PI
A Phase I/IIa Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis$52,510
ZIA · FY2022 · EY · contact PI
AMD Ryan Initiative Study (ARIS)$35,007
ZIA · FY2022 · EY · contact PI
ACCORD (Action to Control Cardiovascular Risk in Diabetes)$35,007
ZIA · FY2022 · EY · contact PI
Age-Related Eye Disease Follow-up Study (AREDS) Follow-up Study$35,007
ZIA · FY2022 · EY · contact PI
A Phase 3 Multicenter, Randomized, Sham-Controlled Study to Determine the Safety and Efficacy of Renexus in Macular Telangiectasia Type 2$35,007
ZIA · FY2022 · EY · contact PI
Phase 2 Clinical Trial of Ciliary Neurotrophic Factor (CNTF) for Macular Telangiectasia Type 2 (MacTel) (14-EI-0078, 17-EI-0136)$35,007
ZIA · FY2022 · EY · contact PI
A Phase I/II Trial for Intravitreous Treatment of Severe Ocular von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab (16-EI-0159)$35,007
ZIA · FY2022 · EY · contact PI
Age-Related Eye Disease Follow-up Study (AREDS) Follow-up Study$31,027
ZIA · FY2021 · EY · contact PI
AMD Ryan Initiative Study (ARIS)$31,027
ZIA · FY2021 · EY · contact PI
ACCORD (Action to Control Cardiovascular Risk in Diabetes)$31,027
ZIA · FY2021 · EY · contact PI
AMD Ryan Initiative Study (ARIS)$29,249
ZIA · FY2020 · EY · contact PI
Age-Related Eye Disease Follow-up Study (AREDS) Follow-up Study$29,249
ZIA · FY2020 · EY · contact PI
ACCORD (Action to Control Cardiovascular Risk in Diabetes)$29,249
ZIA · FY2020 · EY · contact PI
Age-Related Eye Disease Follow-up Study (AREDS) Follow-up Study$55,081
ZIA · FY2019 · EY · contact PI
ACCORD (Action to Control Cardiovascular Risk in Diabetes)$55,081
ZIA · FY2019 · EY · contact PI
AMD Ryan Initiative Study (ARIS)$27,540
ZIA · FY2019 · EY · contact PI
ACCORD (Action to Control Cardiovascular Risk in Diabetes)$54,417
ZIA · FY2018 · EY · contact PI
Age-Related Eye Disease Follow-up Study (AREDS) Follow-up Study$54,417
ZIA · FY2018 · EY · contact PI
AMD Ryan Initiative Study (ARIS)$27,208
ZIA · FY2018 · EY · contact PI
ACCORD (Action to Control Cardiovascular Risk in Diabetes)$52,506
ZIA · FY2017 · EY · contact PI
Age-Related Eye Disease Follow-up Study (AREDS) Follow-up Study$52,506
ZIA · FY2017 · EY · contact PI
Medical Retina Fellowship$194,172
ZIE · FY2016 · EY · contact PI
ACCORD (Action to Control Cardiovascular Risk in Diabetes)$52,479
ZIA · FY2016 · EY · contact PI
Age-Related Eye Disease Follow-up Study (AREDS) Follow-up Study$52,479
ZIA · FY2016 · EY · contact PI
FIND (Familial Investigation of Nephropathy in Diabetes)$10,496
ZIA · FY2016 · EY · contact PI
Medical Retina Fellowship$256,213
ZIE · FY2015 · EY · contact PI
The Age-Related Eye Disease Study 2 (AREDS2)$155,138
ZIA · FY2015 · EY · contact PI
Eval. of Sirolimus in Treatment of Bilateral Geographic Atrophy$141,035
ZIA · FY2015 · EY · contact PI
Age-Related Eye Disease Follow-up Study (AREDS) Follow-up Study$47,012
ZIA · FY2015 · EY · contact PI
ACCORD (Action to Control Cardiovascular Risk in Diabetes)$47,012
ZIA · FY2015 · EY · contact PI
FIND (Familial Investigation of Nephropathy in Diabetes)$9,402
ZIA · FY2015 · EY · contact PI
Medical Retina Fellowship$191,538
ZIE · FY2014 · EY · contact PI
The Age-Related Eye Disease Study 2 (AREDS2)$135,774
ZIA · FY2014 · EY · contact PI
Eval. of Sirolimus in Treatment of Bilateral Geographic Atrophy$130,925
ZIA · FY2014 · EY · contact PI
ACCORD (Action to Control Cardiovascular Risk in Diabetes)$24,245
ZIA · FY2014 · EY · contact PI
Age-Related Eye Disease Follow-up Study (AREDS) Follow-up Study$24,245
ZIA · FY2014 · EY · contact PI
FIND (Familial Investigation of Nephropathy in Diabetes)$9,698
ZIA · FY2014 · EY · contact PI
Medical Retina Fellowship$174,930
ZIE · FY2013 · EY · contact PI
The Age-Related Eye Disease Study 2 (AREDS2)$141,835
ZIA · FY2013 · EY · contact PI
Eval. of Sirolimus in Treatment of Bilateral Geographic Atrophy$141,835
ZIA · FY2013 · EY · contact PI
Age-Related Eye Disease Follow-up Study (AREDS) Follow-up Study$23,639
ZIA · FY2013 · EY · contact PI
ACCORD (Action to Control Cardiovascular Risk in Diabetes)$23,639
ZIA · FY2013 · EY · contact PI
MACTEL2$11,820
ZIA · FY2013 · EY · contact PI
MACTEL1$11,820
ZIA · FY2013 · EY · contact PI
FIND (Familial Investigation of Nephropathy in Diabetes)$9,456
ZIA · FY2013 · EY · contact PI
Medical Retina Fellowship$224,028
ZIE · FY2012 · EY · contact PI
The Age-Related Eye Disease Study 2 (AREDS2)$182,631
ZIA · FY2012 · EY · contact PI
Eval. of Sirolimus in Treatment of Bilateral Geographic Atrophy$158,280
ZIA · FY2012 · EY · contact PI
ACCORD (Action to Control Cardiovascular Risk in Diabetes)$24,351
ZIA · FY2012 · EY · contact PI
Age-Related Eye Disease Follow-up Study (AREDS) Follow-up Study$24,351
ZIA · FY2012 · EY · contact PI
MACTEL1$12,175
ZIA · FY2012 · EY · contact PI
FIND (Familial Investigation of Nephropathy in Diabetes)$12,175
ZIA · FY2012 · EY · contact PI
MACTEL2$12,175
ZIA · FY2012 · EY · contact PI
Medical Retina Fellowship$311,393
ZIE · FY2011 · EY · contact PI
Age-Related Eye Disease Follow-up Study (AREDS) Follow-up Study$32,778
ZIA · FY2011 · EY · contact PI
ACCORD (Action to Control Cardiovascular Risk in Diabetes)$32,778
ZIA · FY2011 · EY · contact PI
MACTEL2$32,778
ZIA · FY2011 · EY · contact PI
MACTEL1$16,389
ZIA · FY2011 · EY · contact PI
FIND (Familial Investigation of Nephropathy in Diabetes)$16,389
ZIA · FY2011 · EY · contact PI
Medical Retina Fellowship$243,488
ZIE · FY2010 · EY · contact PI
ACCORD (Action to Control Cardiovascular Risk in Diabetes)$31,216
ZIA · FY2010 · EY · contact PI
Age-Related Eye Disease Follow-up Study (AREDS) Follow-up Study$31,216
ZIA · FY2010 · EY · contact PI
MACTEL1$15,608
ZIA · FY2010 · EY · contact PI
FIND (Familial Investigation of Nephropathy in Diabetes)$15,608
ZIA · FY2010 · EY · contact PI
MACTEL2$15,608
ZIA · FY2010 · EY · contact PI
SERUM FACTORS IN DIABETIC EYES$15,608
ZIA · FY2010 · EY · contact PI
Medical Retina Fellowship$244,997
ZIE · FY2009 · EY · contact PI
ACCORD (Action to Control Cardiovascular Risk in Diabetes)$30,625
ZIA · FY2009 · EY · contact PI
Age-Related Eye Disease Follow-up Study (AREDS) Follow-up Study$30,625
ZIA · FY2009 · EY · contact PI
FIND (Familial Investigation of Nephropathy in Diabetes)$15,312
ZIA · FY2009 · EY · contact PI
SERUM FACTORS IN DIABETIC EYES$15,312
ZIA · FY2009 · EY · contact PI
Evaluation/diagnosis- Potential Subject-Retinovascular$0
Z01 · FY2005 · EY
Anti-VEGF Pegylated Aptamer for Advanced Ocular Disease$0
Z01 · FY2005 · EY
A Pilot Study of Laser Photocoagulation for Diabetic Mac$0
Z01 · FY2005 · EY
Evaluation of Age-Related Eye Disease Study (AREDS) Clin$0
Z01 · FY2005 · EY
Ranibizumab (rhuFAB V2) for Advanced Ocular Disease of V$0
Z01 · FY2005 · EY
Age-related Eye Disease Study (AREDS)$0
Z01 · FY2005 · EY
SERUM FACTORS IN DIABETIC EYES$0
Z01 · FY2005 · EY
THE RAMAN STUDY$0
Z01 · FY2005 · EY
DPP (Diabetes Prevention Program)$0
Z01 · FY2005 · EY
ACCORD(Action-Control Cardiovascular Risk in Diabetes)$0
Z01 · FY2005 · EY
FIND (Familial Investigation of Nephropathy in Diabetes)$0
Z01 · FY2005 · EY
Diabetic Macular Edema Study$0
Z01 · FY2005 · EY
Evaluation-Treatment Protocol-Patients- Retinal Disease$0
Z01 · FY2005 · EY
Evaluation of AREDS Clinical Lens Grading System$0
Z01 · FY2004 · EY
Optical Coherence Tomography Comparative Study$0
Z01 · FY2004 · EY
Ranibizumab for Advanced Ocular Disease of VHL Disease$0
Z01 · FY2004 · EY
Anti-VEGF Pegylated Aptamer for Advanced Ocular Disease$0
Z01 · FY2004 · EY
Laser Photocoagulation for Diabetic Macular Edema$0
Z01 · FY2004 · EY
SERUM FACTORS IN DIABETIC EYES$0
Z01 · FY2004 · EY
THE RAMAN STUDY$0
Z01 · FY2004 · EY
ACCORD Action to Control Cardiovascular Risk in Diabetes$0
Z01 · FY2004 · EY
DPP (Diabetes Prevention Program)$0
Z01 · FY2004 · EY
FIND (Familial Investigation of Nephropathy in Diabetes)$0
Z01 · FY2004 · EY
Diabetic Macular Edema Study$0
Z01 · FY2004 · EY
Evaluation &Treatment Protocol For Patients$0
Z01 · FY2004 · EY
Screening for Evaluation/Diagnosis Of Potential Subjects$0
Z01 · FY2004 · EY
Age-related Eye Disease Study (AREDS)$0
Z01 · FY2004 · EY
Screening For The Evaluation/diagnosis Of Potential Subj$0
Z01 · FY2003 · EY
Age-related Eye Disease Study (areds)$0
Z01 · FY2003 · EY
ANTIOXIDANT FOR DME$0
Z01 · FY2003 · EY
THE RAMAN STUDY$0
Z01 · FY2003 · EY
ACCORD (Action to Control Cardiovascular Risk in Diabete$0
Z01 · FY2003 · EY
DPP (Diabetes Prevention Program)$0
Z01 · FY2003 · EY
FIND (Familial Investigation of Nephropathy in Diabetes)$0
Z01 · FY2003 · EY
SERUM FACTORS IN DIABETIC EYES$0
Z01 · FY2003 · EY
Diabetic Macular Edema Study$0
Z01 · FY2003 · EY
Range Study Of Lutein Supplementation In Persons Over Ag$0
Z01 · FY2003 · EY
Evaluation And Treatment Protocol For Patients With Reti$0
Z01 · FY2003 · EY
Evaluation And Treatment Protocol of Retinal Disease$0
Z01 · FY2002 · EY
Age-related Eye Disease Study (AREDS)$0
Z01 · FY2002 · EY
Diabetic Macular Edema Study$0
Z01 · FY2002 · EY
Range Study Of Lutein Supplementation Over Age 60$0
Z01 · FY2002 · EY
Screening for Retinovascular Diseases$0
Z01 · FY2002 · EY